| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Akebia Therapeutics Inc. | Vadadustat | COVID-19 | Phase 3 | Ongoing | Oral | COVID-19 |
| Akebia Therapeutics Inc. | Vadadustat | ARDS in subjects with COVID-19 and hypoxemia | Phase 2 | Data Released | Oral | COVID-19 |
| Akebia Therapeutics Inc. | Vadadustat | ARDS in subjects with COVID-19 and hypoxemia | Phase 2 | Data Released | Oral | COVID-19 |
| Akebia Therapeutics Inc. | Vadadustat - (VALOR) | Anemia due to chronic kidney disease (CKD) | Phase 3 | Withdrawn | Oral | Anti-Anemia |
| Alaunos Therapeutics Inc. | Sleeping Beauty - Personalized TCR-T Program | CD19+ leukemias and lymphomas | Phase 2 | Intravenous | Oncology | |
| Alaunos Therapeutics Inc. | Sleeping beauty - TCR-T cell therapy | Solid tumors | Phase 2 | Intravenous | Oncology | |
| Alaunos Therapeutics Inc. | Ad-RTS-hIL-12 plus veledimex plus LIBTAYO (cemiplimab) | Refractory glioblastoma multiforme (GBM) | Phase 2 | Intratumoral oral intravenous | Oncology | |
| Alcon Inc. | ROCLATAN - (Mercury 3) | Open Angle Glaucoma | Phase 3 | Data Released | ophthalmic | Opthalmic |